Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.

Nature communications - 3 Aug 2021

Sun Dapeng, Sang Zhe, Kim Yong Joon, Xiang Yufei, Cohen Tomer, Belford Anna K, Huet Alexis, Conway James F, Sun Ji, Taylor Derek J, Schneidman-Duhovny Dina, Zhang Cheng, Huang Wei, Shi Yi

Abstract excerpt

Interventions against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Stable and potent nanobodies (Nbs) that target the receptor binding domain (RBD) of SARS-CoV-2 spike are promising therapeutics. However, it is unknown if Nbs broadly neutralize circulating variants. We found that RBD Nbs are highly resistant to variants of concern (VOCs). High-resolution...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Broadly Neutralizing Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Epitopes

Share to SARS-CoV-2

Share to Single-Domain Antibodies

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34344900
DOI: 10.1038/s41467-021-24963-3
PMCID: PMC8333356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.PMID 34344900Read ↗

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escapeSemantic proximity Read ↗

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.Semantic proximity Read ↗

Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than OmicronSemantic proximity Read ↗

A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including OmicronSemantic proximity Read ↗

A bivalent spike-targeting nanobody with anti-sarbecovirus activitySemantic proximity Read ↗

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2Semantic proximity Read ↗

A Spike Trimer Dimer-Inducing Nanobody with Anti-Sarbecovirus ActivitySemantic proximity Read ↗

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistanceSemantic proximity Read ↗

Nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variantsSemantic proximity Read ↗

Multivalent designed proteins protect against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2Semantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.